References

  1. 1.Eccles R. Understanding the symptoms of the common cold and influenza. Lancet Infect Dis. 2005;5(11):718-725.
  2. 2.Heikkinen T, Järvinen A. The common cold. Lancet. 2003;361(9351):51-59.
  3. 3.Zhong W, Bragazzi NL, Kong JD, et al. Burden of respiratory infection and tuberculosis among US states from 1990 to 2019. Clin Epidemiol. 2021;13:503-514.
  4. 4.World Health Organization. Pneumonia in children. https://www.who.int/news-room/fact-sheets/detail/pneumonia​
  5. 5.GBD 2021 Lower Respiratory Infections and Antimicrobial Resistance Collaborators. Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Infect Dis. 2024;24(9):974-1002.
  6. 6.He Y, Liu WJ, Jia N, Richardson S, Huang C. Viral respiratory infections in a rapidly changing climate: the need to prepare for the next pandemic. EBioMedicine. 2023;93:104593.
  7. 7.GBD 2021 Upper Respiratory Infections Otitis Media Collaborators. Global, regional, and national burden of upper respiratory infections and otitis media, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Infect Dis. 2025;25(1):36-51.
  8. 8.Li M, Liu M, Liu J. Trends in the mortality, deaths, and aetiologies of lower respiratory infections among 204 countries from 1991 to 2021: an updated systematic study. Viruses. 2025;17(7):892.
  9. 9.GBD 2016 Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018;18(11):1191-1210.
  10. 10.Averin A, Sato R, Begier E, et al. Annual public health and economic burden of medically attended respiratory syncytial virus illnesses among US adults. Vaccine. 2024;42(26):126323.
  11. 11.Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25(27):5086-5096.
  12. 12.Ross I, Bick S, Ayieko P, et al. Effectiveness of handwashing with soap for preventing acute respiratory infections in low-income and middle-income countries: a systematic review and meta-analysis. Lancet. 2023;401(10389):1681-1690.
  13. 13.Mo Y, Pham TM, Lim C, et al. The effect of hand hygiene frequency on reducing acute respiratory infections in the community: a meta-analysis. Epidemiol Infect. 2022;150:e79.
  14. 14.Baier M, Knobloch MJ, Osman F, et al. Effectiveness of mask-wearing on respiratory illness transmission in community settings: a rapid review. Disaster Med Public Health Prep. 2022;17:e96.
  15. 15.Sami H, Firoze S, Khan PA, et al. Face masks for respiratory viral illness prevention in healthcare settings: a concise systemic review and meta-analysis. Iran J Microbiol. 2023;15(2):181-188.
  16. 16.Qian H, Zheng X. Ventilation control for airborne transmission of human exhaled bio-aerosols in buildings. J Thorac Dis. 2018;10:S2295-S2304.
  17. 17.Nawrocki J, Olin K, Holdrege MC, et al. The effects of social distancing policies on non-SARS-CoV-2 respiratory pathogens. Open Forum Infect Dis. 2021;8(7):ofab133.
  18. 18.Jefferson T, Dooley L, Ferroni E, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst Rev. 2023(1):CD006207.
  19. 19.Centers for Disease Control and Prevention. Adenovirus vaccine VIS. https://www.cdc.gov/vaccines/hcp/current-vis/adenovirus.html​
  20. 20.Valleau M, Szablewski CM. Influenza. https://www.cdc.gov/yellow-book/hcp/travel-associated-infections-diseases/influenza.html​
  21. 21.Centers for Disease Control and Prevention. Preventing spread of respiratory viruses when you’re sick. https://www.cdc.gov/respiratory-viruses/prevention/precautions-when-sick.html​
  22. 22.Liang K, Hui P, Green S. Postinfectious cough in adults. CMAJ. 2024;196(5):E157.
  23. 23.El-Radhi AS. Clinical Manual of Fever in Children. El-RadhiAS. Fever in common infectious diseases. In: El RadhiAS, ed.; CarrollJKleinN, editorial advisors. Clinical Manual of Fever in Children. Springer: 2018;85-140.
  24. 24.Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2017(10):CD007498.
  25. 25.Smedemark SA, Aabenhus R, Llor C, et al. Biomarkers as point-ofcare tests to guide prescription of antibiotics in people with acute respiratory infections in primary care. Cochrane Database Syst Rev. 2022(10):CD010130.
  26. 26.Tonkin-Crine SKG, Tan PS, van Hecke O, et al. Clinician-targeted interventions to influence antibiotic prescribing behaviour for acute respiratory infections in primary care: an overview of systematic reviews. Cochrane Database Syst Rev. 2017(9):CD012252.
  27. 27.Rhee C. Using procalcitonin to guide antibiotic therapy. Open Forum Infect Dis. 2016;4(1):ofw249.
  28. 28.Gonçalves PF, Falcão LM, Pinheiro ID. Procalcitonin as biomarker of infection: implications for evaluation and treatment. Am J Ther. 2017;24(3):e243-e249.
  29. 29.Caffarini EM, DeMott J, Patel G, et al. Determining the clinical utility of an absolute procalcitonin value for predicting a positive culture result. Antimicrob Agents Chemother. 2017;61(5):e02007-e02016.
  30. 30.Jullien S, Fitzgerald F, Keddie S, et al. Diagnostic accuracy of multiplex respiratory pathogen panels for influenza or respiratory syncytial virus infections: systematic review and meta-analysis. BMC Infect Dis. 2022;22(1):785.
  31. 31.Llor C, Plate A, Bjerrum L, et al. C-reactive protein point-of-care testing in primary care-broader implementation needed to combat antimicrobial resistance. Front Public Health. 2024;12:1397096.
  32. 32.Zhang K, Xie K, Zhang C, et al. C-reactive protein testing to reduce antibiotic prescribing for acute respiratory infections in adults: a systematic review and meta-analysis. J Thorac Dis. 2022;14(1):123-134.
  33. 33.Ebell MH, Bentivegna M, Cai X, et al. Accuracy of biomarkers for the diagnosis of adult community-acquired pneumonia: a meta-analysis. Acad Emerg Med. 2020;27(3):195-206.
  34. 34.Cohen JF, Pauchard JY, Hjelm N, et al. Efficacy and safety of rapid tests to guide antibiotic prescriptions for sore throat. Cochrane Database Syst Rev. 2020(6):CD012431.
  35. 35.Sheeler RD, Little P. Rapid streptococcal testing for sore throat and antibiotic resistance. Clin Microbiol Infect. 2006;12:3-7.
  36. 36.Dubois C, Smeesters PR, Refes Y, et al. Diagnostic accuracy of rapid nucleic acid tests for group A streptococcal pharyngitis: systematic review and meta-analysis. Clin Microbiol Infect. 2021;27(12):1736-1745.
  37. 37.Guo Z, Zhang Z, Prajapati M, et al. Lymphopenia caused by virus infections and the mechanisms beyond. Viruses. 2021;13(9):1876.
  38. 38.Deckx L, De Sutter AI, Guo L, et al. Nasal decongestants in monotherapy for the common cold. Cochrane Database Syst Rev. 2016(10):CD009612.
  39. 39.Hayward G, Thompson MJ, Perera R, et al. Corticosteroids for the common cold. Cochrane Database Syst Rev. 2015(10):CD008116.
  40. 40.AlBalawi ZH, Othman SS, Alfaleh K. Intranasal ipratropium bromide for the common cold. Cochrane Database Syst Rev. 2013(6):CD008231.
  41. 41.De Sutter AI, Saraswat A, van Driel ML. Antihistamines for the common cold. Cochrane Database Syst Rev. 2015(11):CD009345.
  42. 42.Kim SY, Chang YJ, Cho HM, et al. Non-steroidal anti-inflammatory drugs for the common cold. Cochrane Database Syst Rev. 2015(9):CD006362.
  43. 43.Smith SM, Schroeder K, Fahey T. Over-the-counter (OTC) medications for acute cough in children and adults in community settings. Cochrane Database Syst Rev. 2014(11):CD001831.
  44. 44.King D, Mitchell B, Williams CP, et al. Saline nasal irrigation for acute upper respiratory tract infections. Cochrane Database Syst Rev. 2015(4):CD006821.
  45. 45.Singh M, Singh M, Jaiswal N, et al. Heated, humidified air for the common cold. Cochrane Database Syst Rev. 2017(8):CD001728.
  46. 46.Guppy MP, Mickan SM, Del Mar CB, et al. Advising patients to increase fluid intake for treating acute respiratory infections. Cochrane Database Syst Rev. 2011(2):CD004419.
  47. 47.Hulisz D. Efficacy of zinc against common cold viruses: an overview. J Am Pharm Assoc (2003). 2004;44(5):594-603.
  48. 48.Nault D, Machingo TA, Shipper AG, et al. Zinc for prevention and treatment of the common cold. Cochrane Database Syst Rev. 2024(5):CD014914.
  49. 49.Hemilä H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev. 2013(1):CD000980.
  50. 50.Li-Ng M, Aloia JF, Pollack S, et al. A randomized controlled trial of vitamin D3 supplementation for the prevention of symptomatic upper respiratory tract infections. Epidemiol Infect. 2009;137(10):1396-1404.
  51. 51.Hao Q, Dong BR, Wu T. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev. 2015(2):CD006895.
  52. 52.Karsch-Völk M, Barrett B, Kiefer D, et al. Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev. 2014(2):CD000530.
  53. 53.Fleming-Dutra KE, Hersh AL, Shapiro DJ, et al. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010-2011. JAMA. 2016;315(17):1864-1873.
  54. 54.McDonagh MS, Peterson K, Winthrop K, et al. Interventions to reduce inappropriate prescribing of antibiotics for acute respiratory tract infections: summary and update of a systematic review. J Int Med Res. 2018;46(8):3337-3357.
  55. 55.Kenealy T, Arroll B. Antibiotics for the common cold and acute purulent rhinitis. Cochrane Database Syst Rev. 2025(11):CD000247.
  56. 56.McNicholas M, Hooper G. Effects of patient education to reduce antibiotic prescribing rates for upper respiratory infections in primary care. Fam Pract. 2022;39(1):1-5.
  57. 57.Spurling GKP, Dooley L, Clark J, et al. Immediate versus delayed versus no antibiotics for respiratory infections. Cochrane Database Syst Rev. 2023(10):CD004417.
  58. 58.National Institute of Neurological Disorders and Stroke. Reye’s syndrome. https://www.ninds.nih.gov/health-information/disorders/reyes-syndrome​
  59. 59.Beutler AI, Chesnut GT, Mattingly JC, et al. Aspirin use in children for fever or viral syndromes [FPIN’s Clinical Inquiries]. Am Fam Physician. 2009;80(12):1472.
  60. 60.Englund J, Feuchtinger T, Ljungman P. Viral infections in immunocompromised patients. Biol Blood Marrow Transplant. 2011;17(1):S2-S5.
  61. 61.Regan AK, Rowe SL, Sullivan SG, et al. COVID-19 antiviral medication use among pregnant and recently pregnant US outpatients. Clin Infect Dis. 2025;80(3):512-519.
  62. 62.Centers for Disease Control and Prevention. About influenza. https://www.cdc.gov/flu/about/index.html​
  63. 63.Centers for Disease Control and Prevention. Covid: clinical considerations for special populations. https://www.cdc.gov/covid/hcp/clinical-care/considerations-special-groups.html​
  64. 64.Weir DL, Majumdar SR, McAlister FA, et al. The impact of multimorbidity on short-term events in patients with community-acquired pneumonia: prospective cohort study. Clin Microbiol Infect. 2015;21(3):264.e7-264.e13.
  65. 65.Falsey AR, Walsh EE. Respiratory syncytial virus infection in elderly adults. Drugs Aging. 2005;22(7):577-587.
  66. 66.Hill AT, Gold PM, El Solh AA, et al. Adult outpatients with acute cough due to suspected pneumonia or influenza: CHEST guideline and expert panel report. Chest. 2019;155(1):155-167.
  67. 67.Sur DKC, Plesa ML. Antibiotic use in acute upper respiratory tract infections. Am Fam Physician. 2022;106(6):628-636.
  68. 68.Harris AM, Hicks LA, Qaseem A; High Value Care Task Force of the American College of Physicians and for the Centers for Disease Control and Prevention. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2016;164(6):425-434.
  69. 69.Robinson CP, Busl KM. Neurologic manifestations of severe respiratory viral contagions. Crit Care Explor. 2020;2(4):e0107.
  70. 70.Franczuk P, Tkaczyszyn M, Kulak M, et al. Cardiovascular complications of viral respiratory infections and COVID-19. Biomedicines. 2022;11(1):71.
  71. 71.Zahornacky O, Porubčin Š, Rovnakova A, et al. Multisystem inflammatory syndrome in adults associated with recent infection with COVID-19. Diagnostics (Basel). 2023;13(5):983.
  72. 72.Ebell MH, Merenstein DJ, Barrett B, et al. Acute cough in outpatients: what causes it, how long does it last, and how severe is it for different viruses and bacteria?. Clin Microbiol Infect. 2024;30(12):1569-1575.
  1. 1.Leung NHL, Xu C, Ip DKM, et al. Review article: the fraction of influenza virus infections that are asymptomatic: a systematic review and meta-analysis. Epidemiology. 2015;26(6):862-872.
  2. 2.Killingley B, Nguyen-Van-Tam J. Routes of influenza transmission. Influenza Other Respir Viruses. 2013;7:42-51.
  3. 3.Koçer ZA, Obenauer J, Zaraket H, et al. Fecal influenza in mammals: selection of novel variants. J Virol. 2013;87(21):11476-11486.
  4. 4.Centers for Disease Control and Prevention. How flu spreads. https://www.cdc.gov/flu/spread/index.html​
  5. 5.Xu X, Blanton L, Elal AIA, et al. Update: influenza activity in the United States during the 2018-19 season and composition of the 2019-20 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2019;68(24):544-551.
  6. 6.Centers for Disease Control and Prevention. Weekly US influenza surveillance report: key updates for week 10, ending March 8, 2025. https://www.cdc.gov/fluview/surveillance/2025-week-10.html​
  7. 7.Centers for Disease Control and Prevention. 2024-2025 influenza season summary: severity, disease burden, and burden prevented. flu season. https://www.cdc.gov/flu-burden/php/data-vis-vac/2024-2025-prevented.html​
  8. 8.Reinhart K, Huang S, Kniss K, et al. Influenza-associated pediatric deaths—United States, 2024-25 influenza season. MMWR Morb Mortal Wkly Rep. 2025;74(36):565-569.
  9. 9.Centers for Disease Control and Prevention. Preliminary estimated flu disease burden 2025-2026 flu season. https://www.cdc.gov/flu-burden/php/php/data-vis/2025-2026.html​
  10. 10.Putri WCWS, Muscatello DJ, Stockwell MS, et al. Economic burden of seasonal influenza in the United States. Vaccine. 2018;36(27):3960-3966.
  11. 11.Taubenberger JK, Morens DM. 1918 influenza: the mother of all pandemics. Emerg Infect Dis. 2006;12(1):15-22.
  12. 12.Ma W, Kahn RE, Richt JA. The pig as a mixing vessel for influenza viruses: human and veterinary implications. J Mol Genet Med. 2008;3(1):158-166.
  13. 13.Webster RG, Govorkova EA. H5N1 influenza—continuing evolution and spread. N Engl J Med. 2006;355(21):2174-2177.
  14. 14.Centers for Disease Control and Prevention. A(H5) bird flu: current situation. https://www.cdc.gov/bird-flu/situation-summary/index.html​
  15. 15.Centers for Disease Control and Prevention. H5 bird flu response: focus areas for ongoing public health risk assessment. https://www.cdc.gov/bird-flu/spotlights/h5n1-response-01142025.html​
  16. 16.Macias AE, McElhaney JE, Chaves SS, et al. The disease burden of influenza beyond respiratory illness. Vaccine. 2021;39:A6-A14.
  17. 17.National Institute on Aging. Flu and older adults. https://www.nia.nih.gov/health/flu/flu-and-older-adults​
  18. 18.Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis. 2009;9(8):493-504.
  19. 19.Chen L, Han X, Li YL, et al. The severity and risk factors for mortality in immunocompromised adult patients hospitalized with influenza-related pneumonia. Ann Clin Microbiol Antimicrob. 2021;20(1):55.
  20. 20.Raj RS, Bonney EA, Phillippe M. Influenza, immune system, and pregnancy. Reprod Sci. 2014;21(12):1434-1451.
  21. 21.Wolf RM, Antoon JW. Influenza in children and adolescents: epidemiology, management, and prevention. Pediatr Rev. 2023;44(11):605-617.
  22. 22.Centers for Disease Control and Prevention. People at increased risk for flu complications. https://www.cdc.gov/flu/highrisk/index.htm​
  23. 23.Lansbury LE, Brown CS, Nguyen-Van-Tam JS. Influenza in long-term care facilities. Influenza Other Respir Viruses. 2017;11(5):356-366.
  24. 24.Centers for Disease Control and Prevention. Interim guidance for influenza outbreak management in long-term care and post-acute care facilities. https://restoredcdc.org/www.cdc.gov/flu/hcp/infection-control/ltc-facility-guidance.html​
  25. 25.Miyawaki A, Hasegawa K, Tsugawa Y. Lessons from influenza outbreaks for potential impact of COVID-19 outbreak on hospitalizations, ventilator use, and mortality among homeless persons in New York state. J Gen Intern Med. 2020;35(9):2781-2783.
  26. 26.Rogers JH, Casto AM, Nwanne G, et al. Results from a test-and-treat study for influenza among residents of homeless shelters in King County, WA: a stepped-wedge cluster-randomized trial. Influenza Other Respir Viruses. 2023;17(1):e13092.
  27. 27.Centers for Disease Control and Prevention. Inequities in flu vaccine uptake. https://www.cdc.gov/vitalsigns/flu-inequities/index.html​
  28. 28.Bartsch SM, Taitel MS, DePasse JV, et al. Epidemiologic and economic impact of pharmacies as vaccination locations during an influenza epidemic. Vaccine. 2018;36(46):7054-7063.
  29. 29.Vlahov D, Coady MH, Ompad DC, et al. Strategies for improving influenza immunization rates among hard-to-reach populations. J Urban Health. 2007;84(4):615-631.
  30. 30.Corley AMS, Gomes SM, Crosby LE, et al. Partnering with faith-based organizations to offer flu vaccination and other preventive services. Pediatrics. 2022;150(3):e2022056193.
  31. 31.Steier JB. Using social media to combat influenza vaccine misinformation and improve uptake: a social media campaign and repeated cross-sectional survey analysis. Mayo Clin Proc Digit Health. 2025;3(3):100229.
  32. 32.Gurel-Headley M, Mamisashvili M, CarlLee S, et al. Associations between influenza vaccination and health care access among adults in the United States. Vaccines (Basel). 2023;11(2):416.
  33. 33.Akpalu Y, Sullivan SJ, Regan AK. Association between health insurance coverage and uptake of seasonal influenza vaccine in Brazos County, Texas. Vaccine. 2020;38(9):2132-2135.
  34. 34.Srivastav A, Black CL, Lutz CS, et al. U.S. clinicians’ and pharmacists’ reported barriers to implementation of the Standards for Adult Immunization Practice. Vaccine. 2018;36(45):6772-6781.
  35. 35.Jaca A, Mathebula L, Malinga T, et al. Interventions to improve vaccination uptake among adults: a systematic review and meta-analysis. Vaccines (Basel). 2025;13(8):811.
  36. 36.Loehr J, Savoy M. Strategies for addressing and overcoming vaccine hesitancy. Am Fam Physician. 2016;94(2):94-96.
  37. 37.Shen SC, Dubey V. Addressing vaccine hesitancy: clinical guidance for primary care physicians working with parents. Can Fam Physician. 2019;65(3):175-181.
  38. 38.Grohskopf LA, Blanton LH, Ferdinands JM, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2025-26 influenza season. MMWR Morb Mortal Wkly Rep. 2025;74(32):500-507.
  39. 39.Guo J, Chen X, Guo Y, et al. Real-world effectiveness of seasonal influenza vaccination and age as effect modifier: a systematic review, meta-analysis and meta-regression of test-negative design studies. Vaccine. 2024;42(8):1883-1891.
  40. 40.Centers for Disease Control and Prevention. Flu vaccines and people with egg allergies. https://www.cdc.gov/flu/vaccines/egg-allergies.html​
  41. 41.Centers for Disease Control and Prevention. Seasonal flu vaccine basics. https://www.cdc.gov/flu/vaccines/index.html​
  42. 42.Center for Infectious Disease Research and Policy, University of Minnesota. States, health organizations reject new CDC vaccine guidance. https://www.cidrap.umn.edu/public-health/states-health-organizations-reject-new-cdc-vaccine-guidance​
  43. 43.American Medical Association. Respiratory virus season immunization recommendations. https://www.ama-assn.org/amaone/vaccine-recommendations​
  44. 44.Frutos AM, Cleary S, Reeves EL, et al.; CDC Influenza Vaccine Effectiveness Collaborators. Interim estimates of 2024-2025 seasonal influenza vaccine effectiveness—four vaccine effectiveness networks, United States, October 2024-February 2025. MMWR Morb Mortal Wkly Rep. 2025;74(6):83-90.
  45. 45.Erbelding EJ, Post DJ, Stemmy EJ, et al. A universal influenza vaccine: the strategic plan for the National Institute of Allergy and Infectious Diseases. J Infect Dis. 2018;218(3):347-354.
  46. 46.US Department of Health and Human Services. HHS winds down mRNA vaccine development under BARDA. https://www.hhs.gov/press-room/hhs-winds-down-mrna-development-under-barda.html​
  47. 47.US Food and Drug Administration. MFlusiva. https://www.fda.gov/vaccines-blood-biologics/vaccines/mflusiva​
  48. 48.Leroux-Roels I, Huang G, Ferguson M, et al.; Fluent Trial Investigators. Efficacy and safety of an mRNA seasonal influenza vaccine in adults. N Engl J Med. 2026;394(18):1803-1813.
  49. 49.Antiviral drugs for seasonal influenza for 2024-2025. Med Lett Drugs Ther. 1717;2024(66):193-198.
  50. 50.Zhao Y, Gao Y, Guyatt G, et al. Antivirals for post-exposure prophylaxis of influenza: a systematic review and network meta-analysis. Lancet. 2024;404(10454):764-772.
  51. 51.Antiviral drugs for seasonal influenza for 2025-2026. Med Lett Drugs Ther. 1740;2025(67):169-174.
  52. 52.Dutkowski R. Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients. J Antimicrob Chemother. 2010;65:ii11-ii24.
  53. 53.World Health Organization. Clinical practice guidelines for influenza. https://www.who.int/publications/i/item/9789240097759
  54. 54.Acocal-Juárez E, Márquez-Domínguez L, Vallejo-Ruíz V, et al. Baloxavir resistance markers in influenza A and B viruses in the Americas. Drug Healthc Patient Saf. 2024;16:105-113.
  55. 55.Centers for Disease Control and Prevention. Similarities and differences between flu and COVID-19. https://www.cdc.gov/flu/about/flu-vs-covid19.html​
  56. 56.Haas LEM, Thijsen SFT, van Elden L, et al. Human metapneumovirus in adults. Viruses. 2013;5(1):87-110.
  57. 57.Spencer JA, Shutt DP, Moser SK, et al. Distinguishing viruses responsible for influenza-like illness. J Theor Biol. 2022;545:111145.
  58. 58.Zhang J, Ding D, Huang X, et al. Differentiation of COVID-19 from seasonal influenza: a multicenter comparative study. J Med Virol. 2021;93(3):1512-1519.
  59. 59.Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis. 2019;68(6):895-902.
  60. 60.Centers for Disease Control and Prevention. Rapid influenza diagnostic tests. https://www.cdc.gov/flu/hcp/testing-methods/clinician_guidance_ridt.html​
  61. 61.Centers for Disease Control and Prevention. Overview of influenza testing methods. https://www.cdc.gov/flu/hcp/testing-methods/index.html​
  62. 62.Morris SE, Mathis SM, Reeves E, et al. Modeling the potential impacts of outpatient antiviral treatment in reducing influenza-associated hospitalizations in the United States. J Infect Dis. 2025;232(4):923-932.
  63. 63.Centers for Disease Control and Prevention. Influenza antiviral medications: summary for clinicians. https://www.cdc.gov/flu/hcp/antivirals/summary-clinicians.html​
  64. 64.Centers for Disease Control and Prevention. Treatment of flu in children. https://www.cdc.gov/flu/treatment/children-antiviral.html​
  65. 65.Liu JW, Lin SH, Wang LC, et al. Comparison of antiviral agents for seasonal influenza outcomes in healthy adults and children: a systematic review and network meta-analysis. JAMA Netw Open. 2021;4(8):e2119151.
  66. 66.Centers for Disease Control and Prevention. Treating flu with antiviral drugs. https://www.cdc.gov/flu/treatment/antiviral-drugs.html​
  67. 67.Lehnert R, Pletz M, Reuss A, et al. Antiviral medications in seasonal and pandemic influenza. Dtsch Arztebl Int. 2016;113(47):799-807.
  68. 68.Rosenbloom ST, Daniels TL, Talbot TR, et al. Triaging patients at risk of influenza using a patient portal. J Am Med Inform Assoc. 2012;19(4):549-554.
  69. 69.Koszalka P, Subbarao K, Baz M. Preclinical and clinical developments for combination treatment of influenza. PLoS Pathog. 2022;18(5):e1010481.
  70. 70.Prasso JE, Deng JC. Postviral complications: bacterial pneumonia. Clin Chest Med. 2017;38(1):127-138.
  71. 71.Abdulmuttalib M, Bari A. Influenza: under complications and management, mention needs to be made of secondary bacterial infection and its treatment. Int J Basic Clin Pharmacol. 2025;14(3):411-417.
  72. 72.Thilakaratne D, Bista R, Zenker M, et al. Myocarditis: diagnostic modalities and treatment options. Cureus. 2025;17(3):e79949.
  73. 73.Runnstrom M, Ebied AM, Khoury AP, et al. Influenza-induced rhabdomyolysis. BMJ Case Rep. 2018;11(1):e226610.
  74. 74.National Institute of Neurological Disorders and Stroke. Reye’s syndrome. https://www.ninds.nih.gov/health-information/disorders/reyes-syndrome​
  1. 1.Centers for Disease Control and Prevention. David J. Sencer CDC Museum. CDC museum COVID-19 timeline. https://www.cdc.gov/museum/timeline/covid19.html​
  2. 2.World Health Organization. Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic. https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic​
  3. 3.Du J, Lang HM, Ma Y, et al. Global trends in COVID-19 incidence and case fatality rates (2019-2023): a retrospective analysis. Front Public Health. 2024;12:1355097.
  4. 4.Centers for Disease Control and Prevention. Covid. Surveillance and data analytics. https://www.cdc.gov/covid/php/surveillance/index.html​
  5. 5.Centers for Disease Control and Prevention. Respiratory Illnesses Data Channel. https://www.cdc.gov/respiratory-viruses/data/index.html​
  6. 6.US Department of Health and Human Services. ACIP recommends COVID-19 immunization based on individual decision-making. https://www.hhs.gov/press-room/acip-recommends-covid19-vaccination-individual-decision-making.html​
  7. 7.Zhang B, Wu Q, Jhaveri R, et al.; RECOVER Consortium. Long COVID associated with SARS-CoV-2 reinfection among children and adolescents in the omicron era (RECOVER-EHR): a retrospective cohort study. Lancet Infect Dis. 2026;26(2):127-138.
  8. 8.Lorente-González M, Suarez-Ortiz M, Landete P. Evolution and clinical trend of SARS-CoV-2 variants. Open Respir Arch. 2022;4(2):100169.
  9. 9.Mahilkar S, Agrawal S, Chaudhary S, et al. SARS-CoV-2 variants: impact on biological and clinical outcome. Front Med (Lausanne). 2022;9:995960.
  10. 10.Liu E, Dean CA, Elder KT. Editorial: the impact of COVID-19 on vulnerable populations. Front Public Health. 2023;11:1267723.
  11. 11.Tai DBG, Sia IG, Doubeni CA, et al. Disproportionate impact of COVID-19 on racial and ethnic minority groups in the United States: a 2021 update. J Racial Ethn Health Disparities. 2022;9(6):2334-2339.
  12. 12.Xiong J, Lipsitz O, Nasri F, et al. Impact of COVID-19 pandemic on mental health in the general population: a systematic review. J Affect Disord. 2020;277:55-64.
  13. 13.Bourmistrova NW, Solomon T, Braude P, et al. Long-term effects of COVID-19 on mental health: a systematic review. J Affect Disord. 2022;299:118-125.
  14. 14.Sutton H. Recent research shows dismal outcome for community college enrollment during COVID-19. Enroll Manage Rep. 2021;25(2):9.
  15. 15.Raphael S, Schneider D. Introduction: the socioeconomic impacts of COVID-19. RSF. 2023;9(3):1-30.
  16. 16.Bausch-Jurken M. The hidden cost of COVID: long COVID’s impact on the workforce. https://www.modernatx.com/en-US/media-center/all-media/blogs/Long-COVID-impact-on-the-workforce​
  17. 17.Journal of Health Economics and Outcomes Research. Economic effects of long COVID even larger than we thought. https://jheor.org/post/1746-economic-effects-of-long-covid-even-larger-than-we-thought​
  18. 18.Piacentini J, Frazis H, Meyer PB, et al. The impact of COVID-19 on labor markets and inequality. https://www.bls.gov/osmr/research-papers/2022/pdf/ec220060.pdf​
  19. 19.Pellicori P, Doolub G, Wong CM, et al. COVID-19 and its cardiovascular effects: a systematic review of prevalence studies. Cochrane Database Syst Rev. 2021(3):CD013879.
  20. 20.McCormick B. Telehealth’s pandemic surge: progress achieved, yet challenges persist. https://www.ajmc.com/view/telehealth-s-pandemic-surge-progress-achieved-yet-challenges-persist​
  21. 21.Filip R, Gheorghita Puscaselu R, Anchidin-Norocel L, et al. Global challenges to public health care systems during the COVID-19 pandemic: a review of pandemic measures and problems. J Pers Med. 2022;12(8):1295.
  22. 22.Baskin RG, Bartlett R. Healthcare worker resilience during the COVID-19 pandemic: an integrative review. J Nurs Manag. 2021;29(8):2329-2342.
  23. 23.DeSalvo K, Hughes B, Bassett M, et al. Public health COVID-19 impact assessment: lessons learned and compelling needs. NAM Perspect. 2021;2021:10.31478/202104c.
  24. 24.Twum-Danso N. Strengthening the connections between health care and public health. https://www.ihi.org/library/blog/strengthening-connections-between-health-care-and-public-health​
  25. 25.Neely SR, Witkowski K. Belief in misinformation and acceptance of COVID-19 vaccine boosters: a survey analysis. PEC Innov. 2024;4:100261.
  26. 26.Nussbaumer-Streit B, Mayr V, Dobrescu AI, et al. Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. Cochrane Database Syst Rev. 2020(9):CD013574.
  27. 27.Littlecott H, Krishnaratne S, Burns J, et al. Measures implemented in the school setting to contain the COVID-19 pandemic. Cochrane Database Syst Rev. 2024(5):CD015029.
  28. 28.Kashte S, Gulbake A, El-Amin Iii SF, et al. COVID-19 vaccines: rapid development, implications, challenges and future prospects. Hum Cell. 2021;34(3):711-733.
  29. 29.Centers for Disease Control and Prevention. 2025-2026 COVID-19 vaccination guidance. https://www.cdc.gov/covid/hcp/vaccine-considerations/routine-guidance.html​
  30. 30.Centers for Disease Control and Prevention. Staying up to date with COVID-19 vaccines. https://www.cdc.gov/covid/vaccines/stay-up-to-date.html​
  31. 31.American Academy of Family Physicians. AAFP announces fall immunization recommendations to protect patients and communities. https://www.aafp.org/media-center/press-releases/aafp-announces-fall-immunization-recommendations-to-protect-patients-and-communities​
  32. 32.American College of Obstetricians and Gynecologists. Practice Advisory: COVID-19 vaccination considerations for obstetric–gynecologic care. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care​
  33. 33.Committee on Infectious Diseases. Recommendations for COVID-19 vaccines in infants, children, and adolescents: policy statement. Pediatrics. 2025;156(5):e2025073924.
  34. 34.US Food and Drug Administration. Xocova (ensitrelvir) full prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220442Orig-1s000lbl.pdf​
  35. 35.Hayden FG, Shinkai M, Clark TW, et al.; SCORPIO-PEP Study Team. Ensitrelvir for covid-19 postexposure prophylaxis in household contacts. N Engl J Med. 2026;394(19):1905-1915.
  36. 36.Struyf T, Deeks JJ, Dinnes J, et al.; Cochrane COVID-19 Diagnostic Test Accuracy Group. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19. Cochrane Database Syst Rev. 2022(5):CD013665.
  37. 37.Arshadi M, Fardsanei F, Deihim B, et al. Diagnostic accuracy of rapid antigen tests for COVID-19 detection: a systematic review with meta-analysis. Front Med (Lausanne). 2022;9:870738.
  38. 38.Dinnes J, Berhane S, Walsh J, et al.; Cochrane COVID-19 Diagnostic Test Accuracy Group. Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev. 2025(11):CD013705.
  39. 39.Centers for Disease Control and Prevention. Overview of testing for SARS-CoV-2. https://www.cdc.gov/covid/hcp/clinical-care/overview-testing-sars-cov-2.html​
  40. 40.Zhang Y, Garner R, Salehi S, et al. Molecular and antigen tests, and sample types for diagnosis of COVID-19: a review. Future Virol. 2022;17(9):675-685.
  41. 41.Centers for Disease Control and Prevention. Variants and genomic surveillance. https://www.cdc.gov/covid/php/variants/variants-and-genomic-surveillance.html​
  42. 42.Centers for Disease Control and Prevention. Clinical course: progression, management, and treatment. https://www.cdc.gov/covid/hcp/clinical-care/management-and-treatment.html​
  43. 43.Cheng AM, Dollar E, Angier H. Outpatient management of COVID-19: rapid evidence review. Am Fam Physician. 2023;107(4):370-381.
  44. 44.Centers for Disease Control and Prevention. COVID-19 treatment clinical care for outpatients. https://www.cdc.gov/covid/hcp/clinical-care/outpatient-treatment.html​
  45. 45.Yu SY, Choi M, Ryoo S, et al. Clinical efficacy of inhaled corticosteroids in patients with coronavirus disease 2019: a living review and meta-analysis. PLoS One. 2023;18(11):e0294872.
  46. 46.Hawkins J, Baker C, Cherry L, et al. Black elderberry (Sambucus nigra) supplementation effectively treats upper respiratory symptoms: a meta-analysis of randomized, controlled clinical trials. Complement Ther Med. 2019;42:361-365.
  47. 47.Wieland LS, Piechotta V, Feinberg T, et al. Elderberry for prevention and treatment of viral respiratory illnesses: a systematic review. BMC Complement Med Ther. 2021;21(1):112.
  48. 48.Griesel M, Wagner C, Mikolajewska A, et al. Inhaled corticosteroids for the treatment of COVID-19. Cochrane Database Syst Rev. 2022(3):CD015125.
  49. 49.Cha-Silva AS, Gavaghan MB, Bergroth T, et al. Effectiveness of nirmatrelvir-ritonavir for the prevention of COVID-19–related hospitalization and mortality: a systematic literature review. Am J Ther. 2024;31(3):E246-E257.
  50. 50.Paltra S, Conrad TOF. Clinical effectiveness of ritonavir-boosted nirmatrelvir–a literature review. Adv Respir Med. 2024;92(1):66-76.
  51. 51.Grundeis F, Ansems K, Dahms K, et al. Remdesivir for the treatment of COVID-19. Cochrane Database Syst Rev. 2023(1):CD014962.
  52. 52.Kreuzberger N, Hirsch C, Chai KL, et al. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021(9):CD013825.
  53. 53.Wosik J, Fudim M, Cameron B, et al. Telehealth transformation: COVID-19 and the rise of virtual care. J Am Med Inform Assoc. 2020;27(6):957-962.
  54. 54.Centers for Disease Control and Prevention. Preventing spread of respiratory viruses when you’re sick. https://www.cdc.gov/respiratory-viruses/prevention/precautions-when-sick.html​
  55. 55.Zayed NE, Abbas A, Lutfy SM. Criteria and potential predictors of severity in patients with COVID-19. Egypt J Bronchol. 2022;16(1):11.
  56. 56.Brazier JF, White EM, Meehan A, et al. Rethinking infection control: nursing home administrator experiences during the COVID-19 pandemic. J Am Med Dir Assoc. 2024;25(8):105071.
  57. 57.Centers for Disease Control and Prevention. Infection control guidance: SARS-CoV-2. https://archive.cdc.gov/#/details?url=https://www.cdc.gov/covid/hcp/infection-control/index.html​
  58. 58.Bhimraj A, Falck-Ytter Y, Baden LR, et al. IDSA guidelines on the treatment and management of patients with COVID-19. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/​
  59. 59.Jiang B, Wei H. Oxygen therapy strategies and techniques to treat hypoxia in COVID-19 patients. Eur Rev Med Pharmacol Sci. 2020;24(19):10239-10246.
  60. 60.Amani-Beni R, Kermani-Alghoraishi M, Darouei B, et al. A systematic review on post-discharge venous thromboembolism prophylaxis in patients with COVID-19. Egypt Heart J. 2023;75(1):72.
  61. 61.Moores LK, Tritschler T, Brosnahan S, et al. Thromboprophylaxis in patients with COVID-19: a brief update to the CHEST guideline and expert panel report. Chest. 2022;162(1):213-225.
  62. 62.Barnes GD, Burnett A, Allen A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis. 2020;50(1):72-81.
  63. 63.Lugo GA, Nizami H, Haniff F, et al. Possible long-term cardiovascular effects of COVID-19. Curr Cardiol Rev. 2023;19(2):e160822207545.
  64. 64.Meng M, Wei R, Wu Y, et al. Long-term risks of respiratory diseases in patients infected with SARS-CoV-2: a longitudinal, population-based cohort study. EClinicalMedicine. 2024;69:102500.
  65. 65.Leonel JW, Ciurleo GCV, Formiga AM, et al. Long COVID: neurological manifestations - an updated narrative review. Dement Neuropsychol. 2024;18:e20230076.
  66. 66.Adorjan K, Stubbe HC. Insight into the long-term psychological impacts of the COVID-19 pandemic. Eur Arch Psychiatry Clin Neurosci. 2023;273(2):287-288.
  67. 67.Zawilska JB, Kuczyńska K. Psychiatric and neurological complications of long COVID. J Psychiatr Res. 2022;156:349-360.
  68. 68.Mahalingasivam V, Faucon AL, Sjölander A, et al. Kidney function decline after COVID-19 infection. JAMA Netw Open. 2024;7(12):e2450014.
  69. 69.Frediani MM, Ribeiro HS, Busatto GF, et al. Renal long COVID: a scoping review. Kidney Med. 2025;7(8):S101039.
  70. 70.Knight R, Walker V, Ip S, et al.; CVD-COVID-UK/COVID-IMPACT Consortium and the Longitudinal Health and Wellbeing COVID-19 National Core Study. Association of COVID-19 with major arterial and venous thrombotic diseases: a population-wide cohort study of 48 million adults in England and Wales. Circulation. 2022;146(12):892-906.
  71. 71.Farkouh ME, Stone GW, Lala A, et al. Anticoagulation in patients with COVID-19: JACC Review Topic of the Week. J Am Coll Cardiol. 2022;79(9):917-928.
  1. 1.Oppenlander KE, Chung AA, Clabaugh D. Respiratory syncytial virus bronchiolitis: rapid evidence review. Am Fam Physician. 2023;108(1):52-57.
  2. 2.Perroud AP, Coronel DL, Rivas E. Analyzing seasonal trends of respiratory syncytial virus circulation using Latin American national surveillance database during pre- and post-COVID-19 pandemic. Int J Infect Dis. 2025;161:108095.
  3. 3.Aho S, Ohlsen E. RSV immunization guidance for the 2025-26 season. https://epi.alaska.gov/bulletins/docs/b2025_17.pdf​
  4. 4.Olsen SJ, Winn AK, Budd AP, et al. Changes in influenza and other respiratory virus activity during the COVID-19 pandemic—United States, 2020-2021. MMWR Morb Mortal Wkly Rep. 2021;70(29):1013-1019.
  5. 5.Fitzpatrick T, Buchan SA, Mahant S, et al. Pediatric respiratory syncytial virus hospitalizations, 2017-2023. JAMA Netw Open. 2024;7(6):e2416077.
  6. 6.Kim T, Choi SH. Epidemiology and disease burden of respiratory syncytial virus infection in adults. Infect Chemother. 2024;56(1):1-12.
  7. 7.Popham K, St George K, Felsen C, et al. Disproportionate impact of respiratory syncytial virus (RSV) among older adults in long-term care settings. J Am Med Dir Assoc. 2025;26(9):105760.
  8. 8.Trifonov G, Büscher E, Fistera D, et al. Disease burden of RSV infection in adult patients in comparison to influenza virus infection. J Med Virol. 2025;97(5):e70373.
  9. 9.Colosia A, Costello J, McQuarrie K, et al. Systematic literature review of the signs and symptoms of respiratory syncytial virus. Influenza Other Respir Viruses. 2023;17(2):e13100.
  10. 10.Britton A, Roper LE, Kotton CN, et al. Use of respiratory syncytial virus vaccines in adults aged ≥60 years: updated recommendations of the Advisory Committee on Immunization Practices—United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(32):696-702.
  11. 11.Nodelman M, Scott AM. RSVpreF (Abrysvo) and nirsevimab-alip (Beyfortus) for the prevention of respiratory syncytial virus infection [STEPS]. Am Fam Physician. 2024;109(6):578-579.
  12. 12.Hammitt LL, Dagan R, Yuan Y, et al.; MELODY Study Group. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386(9):837-846.
  13. 13.Centers for Disease Control and Prevention. RSV vaccine guidance for adults. https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/adults.html​
  14. 14.Centers for Disease Control and Prevention. RSV immunization guidance for infants and young children. https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/infants-young-children.html​
  15. 15.Sun M, Lai H, Na F, et al. Monoclonal antibody for the prevention of respiratory syncytial virus in infants and children: a systematic review and network meta-analysis. JAMA Netw Open. 2023;6(2):e230023.
  16. 16.Jones JM, Fleming-Dutra KE, Prill MM, et al. Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices—United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(34):920-925.
  17. 17.Yu J, Liu N, Zhu Y, et al. Comparative study on the epidemiological characteristics and hazards of respiratory syncytial virus and influenza virus infections among elderly people. BMC Infect Dis. 2024;24(1):1129.
  18. 18.Ralston SL, Lieberthal AS, Meissner HC, et al.; American Academy of Pediatrics. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014;134(5):e1474-e1502.
  19. 19.Franklin D, Babl FE, Schlapbach LJ, et al. A randomized trial of high-flow oxygen therapy in infants with bronchiolitis. N Engl J Med. 2018;378(12):1121-1131.
  20. 20.Chartrand C, Tremblay N, Renaud C, et al. Diagnostic accuracy of rapid antigen detection tests for respiratory syncytial virus infection: systematic review and meta-analysis. J Clin Microbiol. 2015;53(12):3738-3749.
  21. 21.Mahony J, Chong S, Merante F, et al. Development of a respiratory virus panel test for detection of twenty human respiratory viruses by use of multiplex PCR and a fluid microbead-based assay. J Clin Microbiol. 2007;45(9):2965-2970.
  22. 22.Feldman C, Anderson R. RSV: an overview of infection in adults. Pneumonia (Nathan). 2025;17(1):15.
  23. 23.Eiland LS. Respiratory syncytial virus: diagnosis, treatment and prevention. J Pediatr Pharmacol Ther. 2009;14(2):75-85.
  24. 24.Hartling L, Wiebe N, Russell K, et al. Epinephrine for bronchiolitis. Cochrane Database Syst Rev. 2004(1):CD003123.
  25. 25.Sigurs N, Gustafsson PM, Bjarnason R, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med. 2005;171(2):137-141.
  26. 26.Mehta GD, Arroyo AC, Zhu Z, et al. Association between severe bronchiolitis in infancy and age 6-year lung function. Respir Med. 2023;218:107401.
  27. 27.Alfano F, Bigoni T, Caggiano FP, Papi A. Respiratory syncytial virus infection in older adults: an update. Drugs Aging. 2024;41(6):487-505.
  28. 28.Manohar P, Loh B, Nachimuthu R, et al. Secondary bacterial infections in patients with viral pneumonia. Front Med (Lausanne). 2020;7:420.
  29. 29.Mazur NI, Caballero MT, Nunes MC. Severe respiratory syncytial virus infection in children: burden, management, and emerging therapies. Lancet. 2024;404(10458):1143-1156.

Current edition

Viral Respiratory Infections

Viral Respiratory Infections

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.